Please wait a minute...
浙江大学学报（医学版）
浙江大学学报（医学版）  2019, Vol. 48 Issue (3): 326-333    DOI: 10.3785/j.issn.1008-9292.2019.06.14
综述     
胃癌早期诊断的血清生物学标志物研究进展
张韵竹(),朱春鹏,陆新良*()
浙江大学医学院附属第二医院消化内科, 浙江 杭州 310009
Advances in serum biomarkers for early diagnosis of gastric cancer
ZHANG Yunzhu(),ZHU Chunpeng,LU Xinliang*()
Department of Gastroenterology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
 全文: PDF(918 KB)   HTML( 29 )
摘要：

早期诊断是胃癌患者良好预后的关键，如何在人群中筛查胃癌高危者是当前的一个热点。基于血清的胃癌早期诊断检测适用于高风险人群筛查，更加方便、安全。本文介绍了胃癌的血清生物学标志物的研究进展，包括血清DNA甲基化、各种RNA、胃蛋白酶原、胃泌素、骨桥蛋白、MG7-Ag和CA724等血清生物学标志物在胃癌诊断方面的价值，并指出寻找胃癌特异的RNA是比较有前景的早期诊断和筛查方法。
关键词： 胃肿瘤/诊断;  胃肿瘤/血液;  生物标记, 肿瘤/血液;  早期诊断;  综述    
Abstract:

Early diagnosis is the key to improve the prognosis of gastric cancer. How to screen out high-risk subjects of gastric cancer in population is a hot spot. Serum-based early detection of gastric cancer is suitable for high-risk population screening, which is more convenient and safer. This article reviews the diagnostic value of serum biomarkers for gastric cancer, including serum DNA methylation, various RNAs, pepsinogen, gastrin, osteopontin, MG7-Ag and CA724. Until now, there is still lack of ideal biomarkers for gastric cancer, and searching for specific RNAs may be promising for early diagnosis and screening of gastric cancer.
Key words: Stomach neoplasms/diagnosis    Stomach neoplasms/blood    Biomarkers, tumor/blood    Early diagnosis    Review
收稿日期: 2018-12-14 出版日期: 2019-09-04
CLC:  R446  
基金资助: 国家自然科学基金(81602516);浙江省自然科学基金(LY17H160022)
通讯作者: 陆新良     E-mail: zyz1109@zju.edu.cn;lux@zju.edu.cn
作者简介: 张韵竹(1995-), 女, 硕士研究生, 主要从事早期胃癌研究; E-mail: zyz1109@zju.edu.cn; https://orcid.org/0000-0001-7819-0631
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　
张韵竹
朱春鹏
陆新良

引用本文:

张韵竹, 朱春鹏, 陆新良. 胃癌早期诊断的血清生物学标志物研究进展[J]. 浙江大学学报（医学版）, 2019, 48(3): 326-333.

ZHANG Yunzhu, ZHU Chunpeng, LU Xinliang. Advances in serum biomarkers for early diagnosis of gastric cancer. J Zhejiang Univ (Med Sci), 2019, 48(3): 326-333.

链接本文:

http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2019.06.14    或    http://www.zjujournals.com/med/CN/Y2019/V48/I3/326

1 王宁, 刘硕, 杨雷 et al. 2018全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2019, 5 (1): 87- 97
WANG Ning , LIU Shuo , YANG Lei et al. Interpretation on the report of Global Cancer Statistics 2018[J]. Journal of Multidisciplinary Cancer Management (Electronic Version), 2019, 5 (1): 87- 97
2 左婷婷, 郑荣寿, 曾红梅 et al. 中国胃癌流行病学现状[J]. 中国肿瘤临床, 2017, 44 (1): 52- 58
ZUO Tingting , ZHENG Rongshou , ZENG Hongmei et al. Epidemiology of stomach cancer in China[J]. Chinese Journal of Clinical Oncology, 2017, 44 (1): 52- 58
doi: 10.3969/j.issn.1000-8179.2017.01.881
3 SIEGEL R , MA J , ZOU Z et al. Cancer statistics[J]. CA Cancer J Clin, 2014, 64 (1): 9- 29
doi: 10.3322/caac.21208
4 YAMASHITA S , KISHINO T , TAKAHASHI T et al. Genetic and epigenetic alterations in normal tissues have differential impacts on cancer risk among tissues[J]. Proc Natl Acad Sci U S A, 2018, 115 (6): 1328- 1333
doi: 10.1073/pnas.1717340115
5 PUNEE T , KAZMI H R , KUMARI S et al. Epigenetic mechanisms and events in gastric cancer-emerging novel biomarkers[J]. Pathol Oncol Res, 2018, 24 (4): 757- 770
doi: 10.1007/s12253-018-0410-z
6 BAYLIN S B , OHM J E . Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction?[J]. Nat Rev Cancer, 2006, 6 (2): 107- 116
doi: 10.1038/nrc1799
7 PATEL T N , ROY S , RAVI R . Gastric cancer and related epigenetic alterations[J]. Ecancermedicalscience, 2017, 11:714
8 WEN J , ZHENG T , HU K et al. Promoter methylation of tumor-related genes as a potential biomarker using blood samples for gastric cancer detection[J]. Oncotarget, 2017, 8 (44): 77783- 77793
9 OOKI A , YAMASHITA K , YAMAGUCHI K et al. DNA damage-inducible gene, reprimo functions as a tumor suppressor and is suppressed by promoter methylation in gastric cancer[J]. Mol Cancer Res, 2013, 11 (11): 1362- 1374
doi: 10.1158/1541-7786.MCR-13-0091
10 BERNAL C , AGUAYO F , VILLARROEL C et al. Reprimo as a potential biomarker for early detection in gastric cancer[J]. Clin Cancer Res, 2008, 14 (19): 6264- 6269
doi: 10.1158/1078-0432.CCR-07-4522
11 Cancer Genome Atlas Research Network . Comprehensive molecular characterization of gastric adenocarcinoma[J]. Nature, 2014, 513 (7517): 202- 209
doi: 10.1038/nature13480
12 LING Z Q , TANAKA A , LI P et al. Microsatellite instability with promoter methylation and silencing of hMLH1 can regionally occur during progression of gastric carcinoma[J]. Cancer Lett, 2010, 297 (2): 244- 251
doi: 10.1016/j.canlet.2010.05.017
13 GRABSCH H I , TAN P . Gastric cancer pathology and underlying molecular mechanisms[J]. Dig Surg, 2013, 30 (2): 150- 158
doi: 10.1159/000350876
14 LEUNG W K , TO K F , CHU E S et al. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer[J]. Br J Cancer, 2005, 92 (12): 2190- 2194
doi: 10.1038/sj.bjc.6602636
15 HU G , QIN L , ZHANG X et al. Epigenetic silencing of the MLH1 promoter in relation to the development of gastric cancer and its use as a biomarker for patients with microsatellite instability:a systematic analysis[J]. Cell Physiol Biochem, 2018, 45 (1): 148- 162
doi: 10.1159/000486354
16 LIU L , YANG X . Implication of reprimo and hMLH1 gene methylation in early diagnosis of gastric carcinoma[J]. Int J Clin Exp Pathol, 2015, 8 (11): 14977- 14982
17 LIN Z , LUO M , CHEN X et al. Combined detection of plasma ZIC1, HOXD10 and RUNX3 methylation is a promising strategy for early detection of gastric cancer and precancerous lesions[J]. J Cancer, 2017, 8 (6): 1038- 1044
doi: 10.7150/jca.18169
18 NI S , YE M , HUANG T . Short stature homeobox 2 methylation as a potential noninvasive biomarker in bronchial aspirates for lung cancer diagnosis[J]. Oncotarget, 2017, 8 (37): 61253- 61263
19 WIELSCHER M , VIERLINGER K , KEGLER U et al. Diagnostic performance of plasma DNA methylation profiles in lung cancer, pulmonary fibrosis and COPD[J]. EBioMedicine, 2015, 2 (8): 929- 936
doi: 10.1016/j.ebiom.2015.06.025
20 HU W , ZHENG W , LIU Q et al. Diagnostic accuracy of DNA methylation in detection of gastric cancer:a meta-analysis[J]. Oncotarget, 2017, 8 (68): 113142- 113152
21 MAEDA M , MORO H , USHIJIMA T . Mechanisms for the induction of gastric cancer by Helicobacter pylori infection:aberrant DNA methylation pathway[J]. Gastric Cancer, 2017, 20 (Suppl 1): 8- 15
22 YANG F , XUE X , ZHENG L et al. Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability[J]. FEBS J, 2014, 281 (3): 802- 813
doi: 10.1111/febs.12625
23 ENDERLE D, SPIEL A, COTICCHIAC M, et al. Characterization of RNA from exosomes and other extracellular vesicles isolated by a novel spin column-based method[J/OL]. PLoS One, 2015, 10(8): e0136133.
24 LIU T , ZHANG X , GAO S et al. Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer[J]. Oncotarget, 2016, 7 (51): 85551- 85563
25 ZHAO R , ZHANG Y , ZHANG X et al. Exosomal long noncoding RNA HOTTIP as potential novel diagnostic and prognostic biomarker test for gastric cancer[J]. Mol Cancer, 2018, 17 (1): 68
doi: 10.1186/s12943-018-0817-x
26 FU M , HUANG Z , ZANG X et al. Long noncoding RNA LINC00978 promotes cancer growth and acts as a diagnostic biomarker in gastric cancer[J]. Cell Prolif, 2018, 51 (1):
27 ZHAO Y , GUO Q , CHEN J et al. Role of long non-coding rnahulc in cell proliferation, apoptosis and tumor metastasis of gastric cancer:a clinical and in vitro investigation[J]. Oncol Rep, 2014, 31 (1): 358- 364
doi: 10.3892/or.2013.2850
28 SHIN V Y , CHU K M . MiRNA as potential biomarkers and therapeutic targets for gastric cancer[J]. World J Gastroenterol, 2014, 20 (30): 10432- 10439
doi: 10.3748/wjg.v20.i30.10432
29 ZHANG Z , LI Z , GAO C et al. miR-21 plays a pivotal role in gastric cancer pathogenesis and progression[J]. Lab Invest, 2008, 88 (12): 1358- 1366
doi: 10.1038/labinvest.2008.94
30 WU J , LI G , WANG Z et al. Circulating microRNA-21 is a potential diagnostic biomarker in gastric cancer[J]. Dis Markers, 2015, 2015:435656
31 YANG R , FU Y , ZENG Y et al. Serum miR-20a is a promising biomarker for gastric cancer[J]. Biomed Rep, 2017, 6 (4): 429- 434
doi: 10.3892/br.2017.862
32 WANG N , WANG L , YANG Y et al. A serum exosomal microRNA panel as a potential biomarker test for gastric cancer[J]. Biochem Biophys Res Commun, 2017, 493 (3): 1322- 1328
doi: 10.1016/j.bbrc.2017.10.003
33 HANSEN T B , JENSEN T I , CLAUSEN B H et al. Natural RNA circles function as efficient microRNA sponges[J]. Nature, 2013, 495 (7441): 384- 388
doi: 10.1038/nature11993
34 MEMCZAK S, PAPAVASILEIOU P, PETERS O, et al. Identification and characterization of circular RNAs as a new class of putative biomarkers in human blood[J/OL]. PLoS One, 2015, 10(10): e0141214.
35 LI W H , SONG Y C , ZHANG H et al. Decreased expression of Hsa_circ_00001649 in gastric cancer and its clinical significance[J]. Dis Markers, 2017, 2017:4587698
36 HUANG M , HE Y R , LIANG L C et al. Circular RNA hsa_circ_0000745 may serve as a diagnostic marker for gastric cancer[J]. World J Gastroenterol, 2017, 23 (34): 6330- 6338
doi: 10.3748/wjg.v23.i34.6330
37 TONG Y , WU Y , SONG Z et al. The potential value of serum pepsinogen for the diagnosis of atrophic gastritis among the health check-up populations in China:a diagnostic clinical research[J]. BMC Gastroenterol, 2017, 17 (1): 88
doi: 10.1186/s12876-017-0641-6
38 KITAHARA F , KOBAYASHI K , SATO T et al. Accuracy of screening for gastric cancer using serum pepsinogen concentrations[J]. Gut, 1999, 44 (5): 693- 697
doi: 10.1136/gut.44.5.693
39 SUN L , TU H , LIU J et al. A comprehensive evaluation of fasting serum gastrin-17 as a predictor of diseased stomach in Chinese population[J]. Scand J Gastroenterol, 2014, 49 (10): 1164- 1172
doi: 10.3109/00365521.2014.950693
40 MIKI K . Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels-"ABC method"[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2011, 87 (7): 405- 414
doi: 10.2183/pjab.87.405
41 IKEDA F , SHIKATA K , HATA J et al. Combination of Helicobacter pylori antibody and serum pepsinogen as a good predictive tool of gastric cancer incidence:20-year prospective data from the hisayama study[J]. J Epidemiol, 2016, 26 (12): 629- 636
doi: 10.2188/jea.JE20150258
42 CHOI H S , LEE S Y , KIM J H et al. Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm[J]. J Dig Dis, 2014, 15 (6): 293- 298
doi: 10.1111/1751-2980.12144
43 YIN L K , SUN X Q , MOU D Z . Value of combined detection of serum CEA, CA72-4, CA19-9 and TSGF in the diagnosis of gastric cancer[J]. Asian Pac J Cancer Prev, 2015, 16 (9): 3867- 3870
doi: 10.7314/APJCP.2015.16.9.3867
44 KUCERA R , SMID D , TOPOLCAN O et al. Searching for new biomarkers and the use of multivariate analysis in gastric cancer diagnostics[J]. Anticancer Res, 2016, 36 (4): 1967- 1971
45 LIANG Y , WANG W , FANG C et al. Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer[J]. Oncotarget, 2016, 7 (31): 49565- 49573
46 GUNALDI M , GOKSU S , ERDEM D et al. Prognostic impact of platelet/lymphocyte and neutrophil/lymphocyte ratios in patients with gastric cancer:a multicenter study[J]. Int J Clin Exp Med, 2015, 8 (4): 5937- 5942
47 WU Y , JIANG M , QIN Y et al. Single and combined use of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and carcinoembryonic antigen in diagnosing gastric cancer[J]. Clin Chim Acta, 2018, 481:20- 24
doi: 10.1016/j.cca.2018.02.027
48 WU C Y , WU M S , CHIANG E P et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival[J]. Gut, 2007, 56 (6): 782- 789
doi: 10.1136/gut.2006.109868
49 CHEN T, SUN L, HE C, et al. Serum OPN expression for identification of gastric cancer and atrophic gastritis and its influencing factors[J/OL]. PLoS One, 2014, 9(12): e114005.
50 ZENG Z , FU S , HU P et al. The diagnostic value of monoclonal gastric cancer 7 antigen:a systematic review with meta-analysis[J]. Clin Exp Med, 2014, 14 (3): 337- 343
doi: 10.1007/s10238-013-0246-5
51 ZHANG L , REN J , PAN K et al. Detection of gastric carcinoma-associated MG7-Ag by serum immuno-PCR assay in a high-risk Chinese population, with implication for screening[J]. Int J Cancer, 2010, 126 (2): 469- 473
doi: 10.1002/ijc.24739
52 SUN L , TU H , CHEN T et al. Three-dimensional combined biomarkers assay could improve diagnostic accuracy for gastric cancer[J]. Sci Rep, 2017, 7 (1): 11621
doi: 10.1038/s41598-017-12022-1
[1] 赵维霞,邹炜. 神经元树突形态建成分子机制的研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 90-99.
[2] 王毅,卢韵碧. 多腺苷二磷酸核糖基化修饰与神经退行性变性疾病[J]. 浙江大学学报（医学版）, 2020, 49(1): 100-106.
[3] 陈峻逸,杨翔,方学贤,王福俤,闵军霞. 铁死亡与重大慢性疾病[J]. 浙江大学学报（医学版）, 2020, 49(1): 44-57.
[4] 俞卿, 熊秀芳, 孙毅. 靶向Cullin-RING E3泛素连接酶的抗肿瘤策略及相关药物研发进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 1-19.
[5] 段玲艳,尹香菊,孟红恩,方学贤,闵军霞,王福俤. 铁稳态代谢表观遗传调控机制的研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 58-70.
[6] 李艾,张添源,高建青. 间充质干细胞的肿瘤归巢特性及其肿瘤靶向治疗应用研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 20-34.
[7] 黄耀凭,杨凤,周天华,谢珊珊. Hippo信号通路及其在消化系统肿瘤中的作用研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 35-43.
[8] 钟文,楼燕,邱宸阳,李栋林,张鸿坤. 髂静脉支架植入术后药物治疗策略研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 131-136.
[9] 徐亦鸣,应可净. 中性粒细胞胞外诱捕网与肿瘤相关研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 107-112.
[10] 刘晓晓,郭莉琼,梁成. 抗N-甲基-D-天冬氨酸受体脑炎患者脑电图特点的研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 118-123.
[11] 方娟,潘志成,郭晓纲. INK4基因座中反义非编码RNA调控细胞增殖与凋亡影响动脉粥样硬化的研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 113-117.
[12] 王诗莹,顾新华. 种植前辅助正畸治疗的临床应用研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 124-130.
[13] 王燚锋, 王志萍. 内源性信号通路在神经元轴突再生中的功能和机制研究[J]. 浙江大学学报（医学版）, 2020, 49(1): 82-89.
[14] 丁怡丹,李文斌,王荣,张建春. 高原低氧对血脑屏障结构及其药物通透性影响的研究进展[J]. 浙江大学学报（医学版）, 2019, 48(6): 668-673.
[15] 李雪,李文斌,封士兰,王荣. 血红蛋白在高原低氧适应中的机制研究进展[J]. 浙江大学学报（医学版）, 2019, 48(6): 674-681.